A Patient and Investigator-blinded, Randomized, Placebo Controlled Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs LLG 783 (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 Sep 2017 Planned End Date changed from 5 Jan 2019 to 18 Jan 2019.
- 26 Sep 2017 Planned primary completion date changed from 5 Jan 2019 to 18 Jan 2019.
- 26 Sep 2017 Status changed from not yet recruiting to recruiting.